Skip to main content
. 2021 Aug 26;238(10):2667–2691. doi: 10.1007/s00213-021-05946-0

Table 6.

An outline of dosing strategies for methylphenidate formulations (approved by the FDA for ADHD in adults)

Brand name Dosing (times per day) Onset of effect Overall duration of effect Dose range/provisional maximum dose
Short-acting
Ritalin® 2–3 1–2 h 4 h

10–60 mg in divided doses

Provisional maximum dose: 150 mg/day

Methylin® 2–3 1 h 4 h
Medikinet CR® 2 5–8 h
Intermediate-acting
Methylin ER® 2–3 n.a n.a n.a
Ritalin SR® 1 1.5 h 8 h n.a
Metadate ER® 1 n.a 8 h n.a
Long-acting
Quillichew ER® 1 45 min 8 h Provisional maximum dose: 150 mg/day
Concerta® 1–2

The immediate-release component ⇒ the first peak plasma concentration: 1–2 h following the ingestion

The slow-release component ⇒ the second peak plasma concentration: about 7 h following the ingestion

7–12 h
Quillivant XR® 1 45 min 12 h
Aptensio XR™ 1 1 h 12 h
Jornay PM® 1 8–10 h  > 12 h
Adhansia XR® 1 1 h 13–16 h

ADHD attention-deficit/hyperactivity disorder, ER/XR extended release, FDA U.S. Food and Drug Administration, n.a. no data available, SR sustained release

Adapted from Banaschewski et al. (2006), Kooij (2013) and Mattingly et al. (2020)